Back to HomeBeta

ICD-10 Coding for Glutamic Acid Decarboxylase Antibody(E10.9, G25.89)

Complete ICD-10-CM coding and documentation guide for Glutamic Acid Decarboxylase Antibody. Includes clinical validation requirements, documentation requirements, and coding pitfalls.

Also known as:

GAD AntibodyGAD-65 Antibody

Related ICD-10 Code Ranges

Complete code families applicable to Glutamic Acid Decarboxylase Antibody

E10-E14Primary Range

Diabetes mellitus

GAD antibodies are used to confirm autoimmune diabetes, primarily type 1 diabetes.

Other extrapyramidal and movement disorders

GAD antibodies are associated with neurological conditions like Stiff-Person Syndrome.

Code Comparison: When to Use Each Code

Compare key differences between these codes to ensure accurate selection

CodeDescriptionWhen to UseKey Documentation
E10.9Type 1 diabetes mellitus without complicationsUse when GAD antibodies confirm autoimmune diabetes etiology.
  • GAD-65 antibody level >1.05 U/mL
  • Hyperglycemia or insulin dependence
G25.89Other specified extrapyramidal and movement disordersUse for confirmed Stiff-Person Syndrome with high GAD antibody titers.
  • GAD-65 antibody level >20,000 U/mL
  • Presence of rigidity and spasms

Clinical Decision Support

Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.

Key Information: ICD-10 code for GAD antibodies

Essential facts and insights about Glutamic Acid Decarboxylase Antibody

The ICD-10 code for GAD antibodies includes E10.9 for autoimmune diabetes and G25.89 for Stiff-Person Syndrome.

Primary ICD-10-CM Codes for glutamic acid decarboxylase

Type 1 diabetes mellitus without complications
Billable Code

Decision Criteria

clinical Criteria

  • Presence of GAD antibodies and insulin dependence

Applicable To

  • Autoimmune diabetes confirmed by GAD antibodies

Excludes

  • Type 2 diabetes mellitus (E11.-)

Clinical Validation Requirements

  • GAD-65 antibody level >1.05 U/mL
  • Hyperglycemia or insulin dependence

Code-Specific Risks

  • Misclassification as type 2 diabetes
  • Lack of documented antibody levels

Coding Notes

  • Ensure documentation of GAD antibody levels and clinical presentation.

Ancillary Codes

Additional codes that should be used in conjunction with the main diagnosis codes when applicable.

Encounter for examination for normal comparison and control in clinical research program

Z00.6
Use when documenting lab tests related to GAD antibodies.

Other abnormal involuntary movements

R25.8
Use to document specific symptoms like muscle rigidity.

Differential Codes

Alternative codes to consider when ruling out similar conditions to the primary diagnosis.

Type 2 diabetes mellitus without complications

E11.9
Type 2 diabetes is typically non-autoimmune and does not involve GAD antibodies.

Multiple sclerosis

G35
Multiple sclerosis involves demyelination, not GAD antibodies.

Documentation & Coding Risks

Avoid these common documentation and coding issues when documenting Glutamic Acid Decarboxylase Antibody to ensure proper reimbursement, maintain compliance, and reduce audit risk. These guidelines are particularly important when using ICD-10 code E10.9.

Impact

Clinical: May lead to misdiagnosis or inappropriate treatment., Regulatory: Non-compliance with documentation standards., Financial: Potential claim denials due to insufficient documentation.

Mitigation Strategy

Always include lab results in the patient's medical record., Ensure linkage between lab results and clinical diagnosis.

Impact

Reimbursement: Incorrect coding may lead to claim denials., Compliance: Non-compliance with coding standards., Data Quality: Inaccurate patient records and data reporting.

Mitigation Strategy

Ensure GAD refers to glutamic acid decarboxylase in the context of diabetes or neurological disorders.

Impact

Failure to document specific GAD antibody levels and clinical indications.

Mitigation Strategy

Implement standardized templates for documenting lab results and clinical findings.

Documentation errors, coding pitfalls, and audit risks are interconnected aspects of medical coding and billing. Addressing all three areas helps ensure accurate coding, optimal reimbursement, and regulatory compliance.

Frequently Asked Questions

Common questions about ICD-10 coding for Glutamic Acid Decarboxylase Antibody, with expert answers to help guide accurate code selection and documentation.

Documentation Templates for Glutamic Acid Decarboxylase Antibody

Use these documentation templates to ensure complete and accurate documentation for Glutamic Acid Decarboxylase Antibody. These templates include all required elements for proper coding and billing.

Autoimmune Diabetes Diagnosis

Specialty: Endocrinology

Required Elements

  • Patient history
  • GAD antibody levels
  • Insulin dependence
  • Clinical presentation

Example Documentation

Patient presents with hyperglycemia and GAD-65 Ab level of 12.5 U/mL. Initiate insulin therapy.

Examples: Poor vs. Good Documentation

Poor Documentation Example
Elevated GAD antibodies noted.
Good Documentation Example
GAD-65 antibody level of 12.5 U/mL confirms autoimmune diabetes. Initiate insulin therapy.
Explanation
The good example provides specific antibody levels and a clear treatment plan.

Need help with ICD-10 coding for Glutamic Acid Decarboxylase Antibody? Ask your questions below.

Ask about any ICD-10 CM code, or paste a medical note

We build tools for
clinician happiness.

Learn More at Freed.ai
Back to HomeBeta

Built by Freed

Try Freed for free for 7 days.

Learn more